IPO roundup: Is the window slamming on life sciences?
It’s sure starting to look that way. News that Archemix, a Cambridge, Mass., developer of aptamer-based drugs, yesterday withdrew its $72.5 million IPO follows closely on the heels of several other recent several other IPO collapses, including those of implantable diagnostic maker Transoma Medical and… Continue Reading
Life sciences briefing: Tuesday, Oct. 23, 2007
Featured companies: Apex Radiology, Arcxis Biotechnologies, EKR Therapeutics, Franklin & Seidelmann, Michelson Diagnostics, SensiGen, Vascular Closure Systems
UPDATED: Expanded items on Arcxis, Vascular Closure and Archemix.
Arcxis pulls in $2M for DNA tools — Arcxis Biotechnologies, a Pleasanton, Calif., biotech tool maker focused on analysis of DNA and proteins… Continue Reading
Life sciences briefing: Monday, Aug. 13, 2007
(UPDATED: See below.)
Featured companies: FoldRx Pharmaceuticals, Ophthotech, Pevion Biotech, Restoration Robotics, Glide Pharma, Reliant Pharmaceuticals, Nanosphere, SurModics, BioFX Laboratories
FoldRx Pharma to receive $22M against cystic fibrosis — Cambridge, Mass.-based FoldRx Pharmaceuticals, a biotech focused on diseases that result from misfolded proteins, will get $22 million over the… Continue Reading
Biotech financing: Will ImaRx break the IPO slump?
(UPDATED: See below.)
It’s been a long, barren summer for biotech IPOs, but ImaRx, the blood-clot company we featured here, finally managed to bull its way into the public markets. The company, which withdrew an earlier $75 million IPO and lowered its offering price on the current… Continue Reading
Aptamer-drug maker Archemix files for $69M IPO
(UPDATED: See below.)